Prevymis for CMV prophylaxis – pro
Prevymis is an antiviral drug that is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). The recommended dosage of Prevymis is 480 mg administered orally once daily.
It is a more effective drug then acyclovir for prophylaxis. A systematic literature review, conventional meta-analysis, and network meta-analysis using a random-effects model and risk ratios (RRs) with corresponding 95% confidence intervals (CIs) as effect estimates. Fifteen randomized controlled trials were identified, including 7 different antiviral agents: acyclovir, ganciclovir, maribavir, brincidofovir, letermovir, valacyclovir, and vaccine. With a probability of 81%, letermovir appears to be the best option in terms of safety.